COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,696 Articles (22,913 medRxiv, 8,783 bioRxiv)

Most recent first Previous |  Page 935: Articles 9341-9350  | Next

Chimeric mRNA based COVID-19 vaccine elicits potent neutralizing antibodies and protection against Omicron and Delta
Hu, Q., Zhao, Y., Shaabani, N., Lyu, X., Sun, H., Cruz, V., Kao, Y., Xu, J., Fossier, A., Stegman, K., Wang, Z., Wang, Z., Hu, Y., Zheng, Y., Kyaw, L., Zuluaga, C., Wang, H., Pei, H., Powers, C., Allen, R., Xie, H., Ji, H., Chen, R.
10.1101/2022.03.04.483032 — Posted: 2022-03-07
Soluble P2X7 receptor is elevated in the plasma of COVID-19 patients and correlates with disease severity
Garcia-Villalba, J., Hurtado-Navarro, L., Penin-Franch, A., Molina-Lopez, C., Martinez-Alarcon, L., Angosto-Bazarra, D., Baroja-Mazo, A., Pelegrin, P.
10.1101/2022.03.04.483019 — Posted: 2022-03-07
Characterization of Hydrophobic Interactions of SARS-CoV-2 and MERS-CoV Spike Protein Fusion Peptides Using Single Molecule Force Measurements
Qiu, C., Whittaker, G., Gellman, S. H., Daniel, S., Abbott, N. L.
10.1101/2022.03.05.483104 — Posted: 2022-03-07
Different forms of superspreading lead to different outcomes: heterogeneity in infectiousness and contact behavior relevant for the case of SARS-CoV-2
Kuylen, E. J., Torneri, A., Willem, L., Libin, P. J. K., Abrams, S., Coletti, P., Franco, N., Verelst, F., Beutels, P., Liesenborgs, J., Hens, N.
10.1101/2022.03.03.22271824 — Posted: 2022-03-06
COVID-19 Hospitalisation in Portugal, the first year: Results from hospital discharge data
Pereira, J. P., Caetano, C., Antunes, L., Patricio, P., Morgado, M. L., Nunes, B.
10.1101/2022.03.03.22271349 — Posted: 2022-03-06
Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study
Shinkai, M., Sonoyama, T., Kamitani, A., Shibata, R., Seki, N., Omoto, S., Shinoda, M., Sato, T., Ishii, N., Igarashi, K., Ariyasu, M.
10.1101/2022.03.03.22271827 — Posted: 2022-03-06
Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children
Puga Gomez, R., Ricardo Delgado, Y., Rojas Iriarte, C., Cespedes Henriquez, L., Bello, M. P., Bello, M. P., Vega Mendoza, D. L., Pestana Perez, N., Paredes-Moreno, B., Rodriguez Gonzalez, M., Valenzuela-Silva, C., Sanchez-Ramirez, B., Rodriguez-Noda, L., Perez Nicado, R., Gonzalez-Mugica, R., Hernandez-Garcia, T., Fundora-Barrios, T., Dubet Echevarria, M., Enriquez-Puertas, J. M., Infante Hernandez, Y., Palenzuela-Diaz, A., Gato Orozco, E., Chappi-Estevez, Y., Francisco-Perez, J. C., Suarez Martinez, M., Castillo-Quintana, I. C., Fernandez-Castillo, S., Climent-Ruiz, Y., Santana-Mederos, D., Garcia-Vega, Y., Toledo-Romani, M. E., Valdes-Balbin, Y., Garcia Rivera, D., Verez-Bencomo, v., SOBERANA Research Group.
10.1101/2022.03.03.22271313 — Posted: 2022-03-06
Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: repeated cross-sectional surveys 2020-21
Lucinde, R. K., Mugo, D., Bottomley, C., Karani, A., Gardiner, E., Aziza, R., Gitonga, J., Karanja, H., Nyagwange, J., Tuju, J., Wanjiku, P., Nzomo, E., Kamuri, E., Thuranira, K., Agunda, S., Nyutu, G., Etyang, A., Adetifa, I. M. O., Kagucia, E., Uyoga, S., Otiende, M., Otieno, E., Ndwiga, L., Agoti, C. N., Aman, R. A., Mwangangi, M., Amoth, P., Kasera, K., Nyaguara, A., Nganga, W., Ochola, L. B., Namdala, E., Gaunya, O., Okuku, R., Barasa, E., Bejon, P., Tsofa, B., Ochola-Oyier, L. I., Warimwe, G. M., Agweyu, A., Scott, J. A. G., Gallagher, K. E.
10.1101/2022.03.03.22271860 — Posted: 2022-03-06
Proteome reveals antiviral host response and NETosis during acute COVID-19 in high-risk patients
Bauer, A., Pachl, E., Hellmuth, J. C., Kneidinger, N., Frankenberger, M., Stubbe, H. C., Ryffel, B., Petrera, A., Hauck, S. M., Behr, J., Kaiser, R., Scherer, C., Deng, L., Teupser, D., Ahmidi, N., Muenchhoff, M., Schubert, B., Hilgendorff, A.
10.1101/2022.03.02.22271106 — Posted: 2022-03-06
Spike mutations of the SARS-CoV-2 Omicron: more likely to occur in the epitopes
Li, H., Chen, Z., Liu, X., Hu, P.
10.1101/2022.03.03.22271159 — Posted: 2022-03-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).